US FDA Awards Orphan Drug Designation (OOD) to Paxalisib for AT/RT, a Rare Form of Childhood Brain Cancer

Kazia Therapeutics Limited announced that the US FDA has awarded ODD to Kazia’s paxalisib for the treatment of atypical rhabdoid / teratoid tumors, a rare and highly aggressive childhood brain cancer.